Skip to main content

Scientific posters

AACR Annual Meeting 2024

Liver toxicity of amanitin-based antibody drug conjugates (ATAC®s) is caused by unspecific uptake of the ATAC® into liver cells

AACR Annual Meeting 2024

HDP-101: The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myelom

AACR Annual Meeting 2024

HDP-102 - a CD37-targeting Amanitin-based-ADC for the treatment of Non-Hodgkin Lymphoma (NHL) - non-clinical data package

AACR Annual Meeting 2024

Multimeric linker exatecan-based ADC targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer

ASH Annual Meeting 2023

HDP-101: An Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

PEGS Boston 2023

In vivo detoxification of Amatoxin-based ADCs (ATACs®) by “Click” chemistry

AACR Annual Meeting 2023

Subcutaneous dosing increases the therapeutic index of Amatoxin-based ADCs

AACR Annual Meeting 2023

Amanitin-based ADCs targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer

ASH Annual Meeting 2022

HDP-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

AACR Annual Meeting 2022

Treatment with ATAC® induces tolerability in preclinical animal models without triggering tolerance

AACR Annual Meeting 2022

ATACs® induce immunogenic cell death and improve the efficacy of immune checkpoint inhibitors

AACR Annual Meeting 2021

Combination of ATACs with Immune checkpoint inhibitors shows synergistic therapeutic effect

AACR Annual Meeting 2021

Preclinical evaluation of anti-CD37 Antibody-Targeted Amanitin Conjugates (ATAC) in B-cell malignancies

AACR Annual Meeting 2021

Amanitin-based ADCs targeting PSMA as novel therapeutic modality for prostate cancer therapy